Clinical potential of lurasidone in the management of schizophrenia

References

• TandonRKeshavanMSNasrallahHASchizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiologySchizophr Res20081021–311818514488
   PubMed Web of Science ®Google Scholar
• KaneJHonigfeldGSingerJMeltzerHClozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazineArch Gen Psychiatry19884597897963046553
   PubMed Web of Science ®Google Scholar
• LiebermanJAMailmanRBDuncanGSerotonergic basis of antipsychotic drug effects in schizophreniaBiol Psychiatry19984411109911179836014
   PubMed Web of Science ®Google Scholar
• BuchananRWKreyenbuhlJKellyDLThe 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull2009361719319955390
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMollerHJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1. Acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl15615000267
   PubMed Web of Science ®Google Scholar
• MooreTABuchananRWBuckleyPFThe Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateJ Clin Psychiatry200768111751176218052569
   PubMed Web of Science ®Google Scholar
• BagnallAMJonesLGinnellyLA systematic review of atypical antipsychotic drugs in schizophreniaHealth Technol Assess2003713119312925268
   PubMedGoogle Scholar
• GeddesJFreemantleNHarrisonPBebbingtonPAtypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysisBMJ200032172731371137611099280
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSSecond-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-analysis of head-to-head comparisonsSchizophr Bull5312010 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophr Res20101232–322523320692814
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationDrug approval package Latuda (lurasidone hydrochloride) tablets Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000TOC.cfm; Accessed May 9, 2010
   Google Scholar
• Latuda (lurasidone HCl) tablets prescribing information Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf; Accessed May 9, 2010.
   Google Scholar
• MeyerJMLoebelADSchweizerELurasidone: A new drug in development for schizophreniaExpert Opin Investig Drugs2009181117151726
   PubMed Web of Science ®Google Scholar
• IshibashiTHorisawaTTokudaKPharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activityJ Pharmacol Exp Ther2010334117118120404009
   PubMed Web of Science ®Google Scholar
• GuscottMBristowLJHadinghamKGenetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depressionNeuropharmacology200548449250215755477
   PubMed Web of Science ®Google Scholar
• MenesesAEffects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning taskBehav Brain Res2004155227528215364487
   PubMed Web of Science ®Google Scholar
• TerryAVJrBuccafuscoJJWilsonCCognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targetsBehav Brain Res20081951303818241938
   PubMed Web of Science ®Google Scholar
• CitromeLLurasidone for schizophrenia: A brief review of a new second-generation antipsychoticClin Schizophr Relat Psychoses20114425125721177242
   PubMedGoogle Scholar
• HarveyPDOgasaMCucchiaroJLoebelAKeefeRSPerformance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidoneSchizophr Res20111271–318819421277745
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJSilvaROgasaMSeversJMarderSREfficacy of lurasidone in schizophrenia: Results of a pooled analysis based on a 5-factor model of schizophreniaSchizophr Res2010117267
   Web of Science ®Google Scholar
• CitromeLLurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychoticInt J Clin Pract201165218921021129135
   PubMed Web of Science ®Google Scholar
• NakamuraMOgasaMGuarinoJLurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trialJ Clin Psychiatry200970682983619497249
   PubMed Web of Science ®Google Scholar
• CucchiaroJPotkinSOgasaMLoebelAA double-blind comparaison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorderSchizophr Bull200935Suppl 1342343
   Google Scholar
• HarveyPDMurasakiMCucchiaroJOgasaMLoebelAA three arm dose finding study of lurasidone: Efficacy and tolerability dataSchizophr Res2010117374375
   Web of Science ®Google Scholar
• GoodKPRabinowitzJWhitehornDHarveyPDDeSmedtGKopalaLCThe relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patientsSchizophr Res2004681111915037335
   PubMed Web of Science ®Google Scholar
• OgasaMLoebelACucchiaroJEffect of lurasidone on depressive symptoms in patients with schizophreniaSchizophr Bull200935344345
   Web of Science ®Google Scholar
• DainipponSecond quarter financial results for FY2010 Presentation slides. Available from: http://www.ds-pharma.com/pdf_view.php?id=55; Accessed May 9, 2010
   Google Scholar
• DainipponCompletion of long-term phase 3 safety trial for Latuda® (lurasidone HCl) Available from: http://www.ds-pharma.com/news/pdf/ene20110125_.pdf; Accessed May 9, 2011
   Google Scholar
• DainipponLatuda meeting January 2011 Presentation slides: Available from: http://www.ds-pharma.com/ir/presentation/img/eir20110125_1.pdf; Accessed May 9, 2011
   Google Scholar
• CucchiaroJPikalovAOgasaMSafety of lurasidone: Pooled analysis of five placebo-controlled trials in patients with schizophreniaInt J Neuropsychopharmacol201013Suppl 121719691873
   PubMed Web of Science ®Google Scholar
• TaylorDPatonCKapurSThe Maudsley Prescribing Guidelines10th EditionLondon, UKInforma Healthcare2009
   Google Scholar
• LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry200970799099619497244
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
   PubMed Web of Science ®Google Scholar
• KarowACzekallaJDittmannRWAssociation of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophreniaJ Clin Psychiatry2007681758017284133
   PubMed Web of Science ®Google Scholar
• LeuchtSKisslingWDavisJMSecond-generation antipsychotics for schizophrenia: Can we resolve the conflict?Psychol Med200939101591160219335931
   PubMed Web of Science ®Google Scholar